Reporting Requirements for Sponsor-Investigators Conducting Investigational New Drug (IND) or Investigational Device Exemption (IDE) Research Policy

Scope

Applies to Sponsor-Investigators when their research involves IND or IDE as required by Mayo Clinic Human Research Protection Program.

Purpose

To state the reporting requirements to track and maintain information regarding sponsor-investigator IND or IDE Food and Drug Administration (FDA) submissions and to assist those sponsor-investigators with compliance per FDA regulations.

Policy

- Mayo Clinic researchers acting as sponsor-investigators and who have an IND or IDE from the FDA must submit relevant documentation of the IND or IDE to the Mayo Clinic Office of Research Regulatory Support (ORRS) or the Cancer Center Compliance Office within 30 calendar days of the IND or IDE effective date. This IND or IDE information is maintained by the ORRS and is to be used to prompt sponsor-investigators of their reporting obligations to the FDA.
- The sponsor-investigator must fulfill additional education requirements to become knowledgeable about his/her additional regulatory obligations as the sponsor of the FDA regulated research. ORRS provides this educational content.

Responsibilities

The sponsor-investigator must:

- Complete educational requirements to become knowledgeable about the additional regulatory obligations they have as the sponsor-investigator of FDA-regulated research.
- Maintain appropriate and up-to-date IND or IDE application documentation in his/her study regulatory files.
- Provide ORRS or the Cancer Center Compliance Office with any additional FDA correspondence regarding his/her IND or IDE within 30 days after receipt.
- Provide a study initiation meeting for the study team before enrolling participants.

The Office of Research Regulatory Support or the Cancer Center Compliance Office:

- Tracks the IND or IDE information in the ORRS IND/IDE database.
• Contacts the sponsor-investigator when annual FDA reports are due.
• Directs sponsor-investigators to templates for sponsor-investigator annual FDA reports.
• Assists the sponsor-investigator with study initiation meetings and provides agenda content.

Policy Notes

N/A

Related Procedures

N/A

Related Documents

ORRS: Sponsor-Investigator Responsibilities Module: IND-IDE Sponsor-Investigator Responsibilities

Mayo Clinic Office of Research Regulatory Support website

Study File Management for Clinical Research Policy

Study File Management for Clinical Research Procedure

Definitions

Food and Drug Administration (FDA): The regulatory authority in the United States (U.S) that oversees the pharmaceutical and medical device industries. The FDA is responsible for ensuring that the drugs and medical devices marketed in the U.S. are safe and have a greater benefit than risk when used according to manufacturer's directions.

Investigational Device Exemption (IDE): Application document submitted to the FDA proposing human clinical research to study an unapproved significant risk device, or a cleared/approved device for use other than its approved indication or intent.

Investigational New Drug (IND): Application document submitted to the FDA proposing human clinical research to study an unapproved drug, or an approved product for a new indication or in a new patient population in a research study.

ORRS: Mayo Clinic Office of Research Regulatory Support

Sponsor-Investigator: An individual who both initiates and conducts an investigation, and under whose immediate direction:

• The investigational drug is administered or dispensed, and or
• The investigational device is administered, dispensed or used. The term does not include any person other than an individual.

References

21 CFR 312: Investigational New Drug Application

21 CFR 812: Investigational Device Exemptions
**Owner**

Kathleen D. McNaughton J.D on behalf of Human Research Protection Program (HRPP)

**Contact**

Angela S. Jurrens

**Revision History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Synopsis of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/02/2021</td>
<td>Scheduled review. Updated Owner and Contact. Link for educational resource and definitions updated.</td>
</tr>
<tr>
<td>09/21/2017</td>
<td>Minor review. Updated the following definitions per Glossary review: Food and Drug Administration (FDA); and Sponsor-Investigator.</td>
</tr>
<tr>
<td>08/22/2017</td>
<td>Scheduled Review - updated to new template - Spelled out ORRS to - Office of Research Regulatory Support. Updated the Cancer Center Regulatory Affairs Unit to Cancer Center Compliance Office. Added: The Sponsor- Investigator must provide a study initiation meeting for the study team prior to enrollment of participants. Added: ORRS to assists the sponsor-investigator with study initiation meetings and provides agenda content. Updated the Owner of document to Karen Hartman with Tammy Neseth as the Contact/reviewer.</td>
</tr>
</tbody>
</table>

**Content Information**

Notification Recipient: Kuntz, Melissa M.
Content ID: DOCMAN-0000057447
Effective Date of Current Version: 08/08/2021
Site(s): Arizona, Florida, Rochester, Barron, Bloomer, Eau Claire, Menomonie, Osseo, Albert Lea, Austin, Cannon Falls, Faribault, Lake City, Owatonna, Red Wing, Fairmont, Mankato, New Prague, St. James, Waseca, La Crosse, Sparta

Workflow Reviewer Name(s): Shanthi L. Siva Shanmuga Sundaram, M.A., M.Phil; Angela S. Jurrens
Workflow Approver Name(s): Kathleen D. McNaughton, J.D.
Scheduled Review Due Date: 08/02/2024

COPYRIGHT © Mayo Foundation for Medical Education and Research. This information is intended for use by employees of Mayo Clinic and its subsidiaries only. It is confidential and no part of it may be transmitted in any form by electronic, mechanical, photocopying, or any other means to anyone outside Mayo Clinic without...
the prior permission of Mayo Foundation for Medical Education and Research. Inappropriate use or dissemination of this information may result in disciplinary action.

Master copies are retained online. Printed copies are considered current only on the date printed.